ZeidKKayaliMD
Gastroenterology • Rialto, CAHepatology & Liver Transplantation
Associate Professor, Medicine, Loma Linda University School of Medicine
Are you Dr. Kayali?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2006 N Riverside Ave
Ste A
Rialto, CA 92377Phone+1 909-883-2999Fax+1 909-883-2997
Summary
- Dr. Zeid Kayali, MD is a gastroenterologist in Rialto, California. He is currently licensed to practice medicine in California, Nevada, and Iowa. He is an Associate Professor at Loma Linda University School of Medicine.
Education & Training
University of Aleppo Faculty of MedicineClass of 1995
Certifications & Licensure
CA State Medical License 2000 - 2026
NV State Medical License 2006 - 2025
IA State Medical License 2001 - 2003
IL State Medical License 1997 - 2002- IL State Medical License 1997 - 2002
American Board of Internal Medicine Gastroenterology- American Board of Internal Medicine Transplant Hepatology
Publications & Presentations
PubMed
- Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?Khaled Al Smadi, Ammar Qureshi, Besher Ashouri, Zeid Kayali
Expert Opinion on Investigational Drugs. 2024-09-01 - Unravelling a Mysterious Skin Lesion in a Patient with Ulcerative Colitis.Khaled Al-Smadi, Ammar Qureshi, Hasan Sqour, Ruijun Jeanna Su, Zeid Kayali
The American Journal of Medicine. 2024-01-01 - Survival and Disease Progression in Older Adult Patients With Cirrhosis: A Retrospective Study.Khaled Al-Smadi, Ammar Qureshi, Michelle Buitrago, Besher Ashouri, Zeid Kayali
International Journal of Hepatology. 2024-01-01
Press Mentions
Kintor Hits Back at Press Criticism of COVID Drug with US Trial UpdateMay 19th, 2021- NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASHAugust 4th, 2023
